NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value

Fair Value

12 Months Ended

Sep. 30, 2022

10. Fair Value

Prior to their expiration during the year ended September 30, 2022, warrant liabilities were measured at fair value on a recurring basis.


	Fair Value Measurements
	as of September 30, 2022
	(Level 1)		(Level 2)	(Level 3)	Total
Liabilities
Warrant liabilities	$	—	—	—	$	—


	Fair Value Measurements
	as of September 30, 2021
	(Level 1)		(Level 2)	(Level 3)	Total
Liabilities
Warrant liabilities	$	—	—	—	$	—

The following assumptions were used in determining the fair value of the warrant liabilities as of September 30, 2021:


		As of September 30, 2021
Remaining contractual term (years)		0.2 - 0.5
Common stock price volatility		60.6% - 62.5%
Risk-free interest rate		0.04%
Expected dividend yield		—

During the year ended September 30, 2021, the Company utilized its historical volatility in the valuation of warrant liabilities as it had sufficient trading activity.

The change in fair value of the warrant liabilities for the years ended September 30, 2022 and 2021 is as follows:


Fair value as of September 30, 2020	$	950,151
Change in fair value		(950,151)
Fair value as of September 30, 2021		—
Change in fair value		—
Fair value as of September 30, 2022	$	—

As of September 30, 2022 and 2021, the recorded values of cash and cash equivalents, accounts payable and the insurance note payable approximate fair value due to the short-term nature of the instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details